Shares of Azurrx Biopharm (NASDAQ:AZRX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $8.25 for the company, according to Zacks. Zacks has also assigned Azurrx Biopharm an industry rank of 111 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $8.00 target price on Azurrx Biopharm and gave the company a “buy” rating in a research report on Friday.
Azurrx Biopharm (NASDAQ:AZRX) traded up $0.13 during midday trading on Friday, reaching $3.04. The company had a trading volume of 41,500 shares, compared to its average volume of 32,986. Azurrx Biopharm has a 12 month low of $2.40 and a 12 month high of $5.25.
Azurrx Biopharm Company Profile
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Azurrx Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azurrx Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.